Skip to main content
MedPathMedPath Home
Clinical Trials/NCT06132191
NCT06132191
Approved For Marketing
Not Applicable

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Regeneron Pharmaceuticals0 sitesStarted: November 15, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsCemiplimab

Overview

Phase
Not Applicable
Status
Approved For Marketing
OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

Provide expanded access of cemiplimab in patients with solid tumors

Detailed Description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

Study Design

Study Type
Expanded Access

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

No Longer Available
Not Applicable
Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma
NCT03492489Regeneron Pharmaceuticals
No Longer Available
Not Applicable
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and GliomasGlioblastomaGlioma of Brain
NCT03460782Center Trials & Treatment
No Longer Available
Not Applicable
Expanded Access for Pembrolizumab (MK-3475)Melanoma (Skin)Melanoma RecurrentGlioblastoma MultiformeGlioblastoma by Gene Expression ProfileGlioma of Brain
NCT03311542Center Trials & Treatment
No Longer Available
Not Applicable
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene FusionSolid Tumors Harboring NTRK Fusion
NCT03206931Bayer
No Longer Available
Not Applicable
Individual Patient Expanded Access-Glembatumumab VedotinMetastatic gpNMB Expressing Triple Negative Breast Cancer
NCT03067935Celldex Therapeutics